The concern of generic rivalry has consistently loomed around copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the outlook of similar pharmaceutical ventures. While first periods saw significant profits, the patent lapse has created the door for discounted alternatives, possibly lowering profitability and presenting a signifi